Paysign, Inc.

Paysign, Inc. reported strong financial results for the second quarter and first half of 2026, with significant increases in revenue and net income. The company's Q2 revenue grew by 48% to $28.25 million, and diluted EPS rose to $0.11. Additionally, Paysign terminated the contingent consideration related to its March 2025 acquisition of Gamma Innovation LLC, with the liability reduced to $0 due to lower-than-expected revenue from acquired technologies.

Paysign, Inc. reported record financial results for the second quarter of 2026, with revenue increasing 48.1% to $28.25 million. This growth was driven by strong performance in both its patient affordability and plasma businesses, leading to a significant rise in GAAP net income to $6.76 million and Adjusted EBITDA to $9.61 million. The company also raised its full-year 2026 outlook for both revenue and Adjusted EBITDA, reflecting continued momentum and a robust pipeline of opportunities.

Paysign reported strong first-quarter 2026 financial results, with total revenues increasing by 50.8% year-over-year to $28.0 million. Net income more than doubled, rising 110.4% to $5.4 million, while basic earnings per share also saw a significant increase. The company also demonstrated a substantial improvement in cash flow from operations, moving from a negative to a positive figure.

Paysign, Inc. reported strong financial results for the first quarter of 2026, with total revenues increasing by 50.8% to $28.04 million and net income more than doubling to $5.44 million. This growth was primarily driven by a significant increase in patient affordability (pharma) revenue, which rose 81.9%, and continued expansion in plasma revenue. The company also achieved substantial margin expansion and reiterated its full-year 2026 guidance, expecting net income to nearly double over 2025.